Recent Company News

• 02:43 PM ET Nov 05, 2026
  

  Transcript Intelligence: ZAI Lab Q3 Earnings Guidance ($22.50, -0.30)

• 02:43 PM ET Nov 05, 2026
  

  Transcript Intelligence: ZAI Lab Q3 Earnings Themes ($22.50, -0.30)

• 02:43 PM ET Nov 05, 2026
  

  Transcript Intelligence: ZAI Lab Q3 Earnings Q&A ($22.50, -0.30)

• 09:04 AM ET Nov 05, 2026
  

  Zai Lab presents updated clinical data on Zocilurtatug Pelitecan (Zoci) in previously treated Extrapulmonary Neuroendocrine carcinomas ($22.80, 0.00)

• 06:46 AM ET Nov 05, 2026
  

  StreetAccount Metrics Recap - ZAI Lab Q3 Earnings ($22.80, 0.00)

• 06:43 AM ET Nov 05, 2026
  

  ZAI Lab reports Q3 revenue $108.2M vs FactSet $107.9M [6 est, $105.0-112.3M] ($22.80, 0.00)

• 12:43 PM ET Nov 04, 2026
  

  Avoiding Lag: Real-Time Signals in (ZLAB) Movement

• 09:45 PM ET Nov 02, 2026
  

  StreetAccount Consensus Metrics Preview - ZAI Lab Q3 Earnings (HK$16.95, -0.33)

• 05:18 PM ET Oct 27, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:31 AM ET Oct 27, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market